Research programme: sorbitol dehydrogenase inhibitors - Pfizer
Latest Information Update: 05 Sep 2006
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic complications
Most Recent Events
- 05 Sep 2006 Discontinued - Preclinical for Diabetic complications in USA (unspecified route)
- 16 Apr 2003 Preclinical trials in Diabetic complications in USA (unspecified route)